Entities / Company
HUMIRA.
Czech company
- Reports this week
- 1
- Active events
- 2
- Connections
- 21
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Active this week
Earlier this month
One to three months ago
Gone quiet
No new reports in 90+ days-
AbbVie and others are managing drug exclusivity, seeking next-gen immunology pipeline growth, and competing for market share.Well supported3 reports3 developments inside
-
cAMPfield Therapeutics is seeking alternatives to drugs like Humira, while Blackstone invests in drug development deals.Some support1 report
-
The patent expiry of Humira is weighing on sentiment, influenced by geopolitical uncertainty in the Middle East.Some support2 reports
-
AbbVie, which lost exclusivity for Humira, is facing potential tariffs on pharmaceutical imports from the Trump administration.Speculative2 reports
-
Declining sales of Humira due to biosimilar erosion.Well supported7 reports1 development inside
-
Johnson & Johnson tested nipocalimab against Humira, while Amgen is noted for biosimilar competition in the market for Humira.Some support1 report1 development inside
-
MoonLake Immunotherapeutics' sonelokimab demonstrated superior performance compared to Humira in multiple Psoriasis metrics.Some support2 reports
-
FDA recognized Hadlima as an interchangeable biosimilar for Humira, supporting Organon's biosimilars pipeline.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around HUMIRA this week
News at the entities that move HUMIRA most-
AbbVie StructuralAbbVie and Cerevel Therapeutics successfully launched a new drug for Parkinson's disease, pending government coverage negotiations.Moves HUMIRA
-
Bristol-Myers Squibb StructuralBristol-Myers Squibb is developing innovative treatments and supporting Cyprus' national effort in haematology.Moves HUMIRA
-
Medicare OperationalLeaders call for slowing AI development pace, concurrent with an AI model built by OpenAI being hacked via the Medicare portal.Moves HUMIRA
-
Eli Lilly and Company OperationalExxonMobil, Berkshire Hathaway, and Eli Lilly are top holdings in the Avantis ETF.Moves HUMIRA
-
Europe Shared contextThe European Central Bank is forced to raise interest rates due to energy price shocks from the Iran war and an influx of Chinese exports.Moves HUMIRA
-
Harvard Medical School Mentioned togetherFatima Cody Stanford is now an associate professor at Harvard Medical School, coinciding with discussions on the wide variation in state-level obesity rates across the U.S.Moves HUMIRA
Connections
The 8 strongest of 21, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
AbbVie Structural
AbbVie manages HUMIRA as a legacy asset, navigating its lifecycle, patent loss, and biosimilar competition while transitioning its portfolio.
-
Bristol-Myers Squibb Structural
The company utilizes the product as a core part of its therapeutic offerings, which are currently facing market pressures from biosimilar competition.
-
Alvotech Operational
Alvotech is developing a biosimilar product intended to compete directly with Humira in the market.
-
Eli Lilly and Company Operational
The relationship is characterized by market competition, where Eli Lilly's growth offsets the decline of Humira.
-
Vanderbilt University School of Medicine Shared context
The entities share a relevant research/market context as biosimilar drugs targeting the same conditions as Humira.
-
Harvard Medical School Mentioned together
HMS researchers are studying the biosimilar competition and generic market dynamics surrounding the drug HUMIRA.
-
Medicare Operational
Medicare operates in a market where generic and biosimilar competition drives down prices, affecting HUMIRA's competitive landscape.
-
Europe Shared context
Humira's patent protection was lost in Europe.
History
Events by the month they beganSeptember 2026
1 eventJune 2026
12 events- AbbVie's product portfolio was bolstered by the acquisition of Allergan, while Humira sales faced erosion due to patent loss and biosimilar competition.
- Lost patent protection for Humira in the US on August 20, 2025.
- AbbVie products are succeeding Humira in the market, while FDA approvals and Fed caution influence market expectations.
- AbbVie's Humira is losing exclusivity and facing intense competition from Skyrizi and Rinvoq.
- AbbVie and others are managing drug exclusivity, seeking next-gen immunology pipeline growth, and competing for market share.
- cAMPfield Therapeutics is seeking alternatives to drugs like Humira, while Blackstone invests in drug development deals.
- The patent expiry of Humira is weighing on sentiment, influenced by geopolitical uncertainty in the Middle East.
- AbbVie, which lost exclusivity for Humira, is facing potential tariffs on pharmaceutical imports from the Trump administration.
- Declining sales of Humira due to biosimilar erosion.
- Johnson & Johnson tested nipocalimab against Humira, while Amgen is noted for biosimilar competition in the market for Humira.
- MoonLake Immunotherapeutics' sonelokimab demonstrated superior performance compared to Humira in multiple Psoriasis metrics.
- FDA recognized Hadlima as an interchangeable biosimilar for Humira, supporting Organon's biosimilars pipeline.